Cargando…

Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer

Androgen deprivation therapy (ADT) is successfully used in patients with advanced prostatic cancer, but there are many concerns about its systemic side effects, especially due to advanced age and frequent comorbidities in most patients. In patients treated with ADT there are metabolic changes involv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gheorghe, Gabriela Silvia, Hodorogea, Andreea Simona, Ciobanu, Ana, Nanea, Ioan Tiberiu, Gheorghe, Andrei Cristian Dan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482210/ https://www.ncbi.nlm.nih.gov/pubmed/34590590 http://dx.doi.org/10.3390/curroncol28050289

Ejemplares similares

Evolution of Electrocardiographic Repolarization Parameters During Antiandrogen Therapy in Patients with Prostate Cancer and Hypogonadism
por: Gheorghe, Andrei Cristian Dan, et al.
Publicado: (2020)

Subclinical left ventricular dysfunction in men under androgen deprivation therapy for prostate cancer, revealed by speckle‐tracking‐derived parameters, repolarization, and myocardial injury markers
por: Gheorghe, Andrei C. D., et al.
Publicado: (2021)

Medical management of symptomatic severe aortic stenosis in patients non-eligible for transcatheter aortic valve implantation
por: Gheorghe, Gabriela Silvia, et al.
Publicado: (2020)

Diagnostic Pitfalls in a Man with Systemic Lupus Erythematous
por: Dan Gheorghe, Andrei Cristian, et al.
Publicado: (2019)

Particular etiology in a case of peripheral tetraparesis
por: Gheorghe, Gabriela S., et al.
Publicado: (2019)

Particular evolution in a 72-year-old diabetic patient with acute coronary syndrome
por: Gheorghe, Gabriela S, et al.
Publicado: (2018)

Decision of Anticoagulation in Nonvalvular Atrial Fibrillation in the Real World in the Non-Antivitamin K Anticoagulants Era
por: Gheorghe, Gabriela Silvia, et al.
Publicado: (2022)

Cardiovascular Toxicities of Androgen Deprivation Therapy
por: Challa, Azariyas A., et al.
Publicado: (2021)

Cardiovascular Toxicity of Androgen Deprivation Therapy
por: Boland, Julia, et al.
Publicado: (2021)

Electrocardiographic measures of repolarization dispersion and their relationships with echocardiographic indices of ventricular remodeling and premature ventricular beats in hypertension
por: Ciobanu, Ana, et al.
Publicado: (2017)

Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer
por: Fradin, James, et al.
Publicado: (2023)

Dispersion of ventricular repolarization in relation to cardiovascular risk factors in hypertension
por: Ciobanu, A, et al.
Publicado: (2014)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
por: Corona, Giovanni, et al.
Publicado: (2021)

Androgen Deprivation Therapy Toxicity and Management for Men Receiving Radiation Therapy
por: Johnson, Matthew E., et al.
Publicado: (2012)

Cardiovascular toxicities of androgen deprivation therapy in Asian men with localized prostate cancer after curative radiotherapy: a registry-based observational study
por: Li, Youquan, et al.
Publicado: (2022)

Metabolic Complications and Increased Cardiovascular Risks as a Result of Androgen Deprivation Therapy in Men with Prostate Cancer
por: Shastri, Bhavin R., et al.
Publicado: (2011)

Androgen deprivation and SARS-CoV-2 in men with prostate cancer
por: Koskinen, M., et al.
Publicado: (2020)

SUN-083 Hypertension and Hemodynamic Parameters in Men with Hypogonadism Improve Under Long-Term Treatment with Testosterone Undecanoate Injections (TU) Compared to Untreated Hypogonadal Control Patients
por: Saad, Farid, et al.
Publicado: (2019)

Cardiovascular Disease Risk Factors: How Relevant in African Men With Prostate Cancer Receiving Androgen-Deprivation Therapy?
por: Essien, Okon Ekwere, et al.
Publicado: (2016)

Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
por: Morrison, Belinda F, et al.
Publicado: (2011)

Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer
por: Gagliano-Jucá, Thiago, et al.
Publicado: (2018)

Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer
por: Liu, Jui-Ming, et al.
Publicado: (2021)

The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer
por: Shah, Neil J, et al.
Publicado: (2022)

Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer
por: Roayaei, Mahnaz, et al.
Publicado: (2013)

Elderly men over 65 years of age with late-onset hypogonadism benefit as much from testosterone treatment as do younger men
por: Saad, Farid, et al.
Publicado: (2015)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Androgen Deprivation Therapy and Cardiovascular Risk
por: Mourmouris, Panagiotis, et al.
Publicado: (2012)

CARDIOVASCULAR DISEASES AND ANDROGEN DEPRIVATION THERAPY
por: Boban, Marko
Publicado: (2019)

Survival following primary androgen deprivation therapy among men with localized prostate cancer
por: Vasudeva, Pawan, et al.
Publicado: (2008)

A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy
por: Lee, C Ellen, et al.
Publicado: (2012)

Androgen Deprivation Therapy Reversibly Increases Endothelium‐Dependent Vasodilation in Men With Prostate Cancer
por: Nguyen, Paul L., et al.
Publicado: (2015)

Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer
por: Jayadevappa, Ravishankar, et al.
Publicado: (2019)

Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer
por: Shore, Richard, et al.
Publicado: (2021)

Two Elderly Men with Myasthenia Gravis during Androgen Deprivation Therapy for Prostate Cancer
por: Kanazawa, Kazo, et al.
Publicado: (2023)

Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer
por: Marshall, Catherine H., et al.
Publicado: (2021)

Androgen Deprivation Therapy and Cardiovascular Risk in Chinese Patients with Nonmetastatic Carcinoma of Prostate
por: Huang, Gang, et al.
Publicado: (2014)

Androgen Treatment in Adolescent Males With Hypogonadism
por: Rey, Rodolfo A., et al.
Publicado: (2020)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy
por: Neubecker, Katherine, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_q07uqsr9su3i0v9npohq49s5or